BioVersys AG (SWX:BIOV)

Switzerland flag Switzerland · Delayed Price · Currency is CHF
29.90
+0.40 (1.36%)
At close: Apr 28, 2026
-12.32%
Market Cap 172.52M
Revenue (ttm) 3.18M
Net Income (ttm) -21.83M
Shares Out 5.85M
EPS (ttm) -3.89
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 821
Average Volume 2,384
Open 28.50
Previous Close 29.50
Day's Range 28.50 - 29.90
52-Week Range 21.20 - 36.00
Beta n/a
RSI 52.26
Earnings Date Sep 3, 2026

About BioVersys AG

BioVersys AG researches and develops antimicrobial drugs for bacterial infections. It develops BV100 that is in Phase 3 clinical trial for carbapenem-resistant Acinetobacter baumannii lung and bloodstream infections. The company is also developing Alpibectir, which is in Phase 2 clinical trial for the treatment of pulmonary and meningeal tuberculosis; BV200 to treat patients with Gram-positive S. aureus; and BV500 for non-tuberculous mycobacteria infections. It has a research and license option agreement with Shionogi & Co., Ltd. to develop ans... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 33
Stock Exchange SIX Swiss Exchange
Ticker Symbol BIOV
Full Company Profile

Financial Performance

In 2025, BioVersys AG's revenue was 3.18 million, an increase of 161.75% compared to the previous year's 1.21 million. Losses were -21.83 million, 16.6% more than in 2024.

Financial Statements

News

There is no news available yet.